Interaction of systemic drugs causing ocular toxicity with organic cation transporter: an artificial intelligence prediction

References

• Al-Karmalawy, A. A., Dahab, M. A., Metwaly, A. M., Elhady, S. S., Elkaeed, E. B., Eissa, I. H., & Darwish, K. M. (2021). Molecular docking and dynamics simulation revealed the potential inhibitory activity of ACEIs against SARS-CoV-2 targeting the h ACE2 receptor. Frontiers in Chemistry, 9, 661230. https://doi.org/10.3389/fchem.2021.661230
   PubMed Web of Science ®Google Scholar
• Ali, A., Shah, A. A., Jeang, L. J., Fallgatter, K. S., George, T. J., & DeRemer, D. L. (2022). Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know. Cancer Treatment Reviews, 105, 102376. https://www.sciencedirect.com/science/article/pii/S0305737222000408. https://doi.org/10.1016/j.ctrv.2022.102376
   PubMed Web of Science ®Google Scholar
• Amir, M., Mohammad, T., Kumar, V., Alajmi, M. F., Rehman, M. T., Hussain, A., Alam, P., Dohare, R., Islam, A., Ahmad, F., & Hassan, M. I. (2019). Structural analysis and conformational dynamics of STN1 gene mutations involved in coat plus syndrome. Frontiers in Molecular Biosciences, 6, 41. https://doi.org/10.3389/fmolb.2019.00041
   PubMed Web of Science ®Google Scholar
• Ashburn, T. T., & Thor, K. B. (2004). Drug repositioning: Identifying and developing new uses for existing drugs. Nature Reviews. Drug Discovery, 3(8), 673–683. https://doi.org/10.1038/nrd1468
   PubMed Web of Science ®Google Scholar
• Baidya, A. T., Ghosh, K., Amin, S. A., Adhikari, N., Nirmal, J., Jha, T., & Gayen, S. (2020). In silico modelling, identification of crucial molecular fingerprints, and prediction of new possible substrates of human organic cationic transporters 1 and 2. New Journal of Chemistry, 44(10), 4129–4143. https://doi.org/10.1039/C9NJ05825G
   Web of Science ®Google Scholar
• Bindiganavile, S. H., Bhat, N., Lee, A. G., Gombos, D. S., & Al-Zubidi, N. (2021). Targeted cancer therapy and its ophthalmic side effects: A review. Journal of Immunotherapy and Precision Oncology, 4(1), 6–15. https://doi.org/10.36401/JIPO-20-21
   PubMedGoogle Scholar
• Brock, W. J., Somps, C. J., Torti, V., Render, J. A., Jamison, J., & Rivera, M. I. (2013). Ocular toxicity assessment from systemically administered xenobiotics: Considerations in drug development. International Journal of Toxicology, 32(3), 171–188. https://doi.org/10.1177/1091581813484500
   PubMed Web of Science ®Google Scholar
• Bussi, G., & Laio, A. (2020). Using metadynamics to explore complex free-energy landscapes. Nature Reviews Physics, 2(4), 200–212. https://doi.org/10.1038/s42254-020-0153-0
   Google Scholar
• Castells, D. D., Teitelbaum, B. A., & Tresley, D. J. (2002). Visual changes secondary to initiation of amiodarone: A case report and review involving ocular management in cardiac polypharmacy. Optometry: Journal of the American Optometric Association.
   Google Scholar
• Coleman, J. J., & Pontefract, S. K. (2016). Adverse drug reactions. Clinical Medicine (London, England), 16(5), 481–485. https://doi.org/10.7861/clinmedicine.16-5-481
   PubMed Web of Science ®Google Scholar
• Constable, P. A., Al-Dasooqi, D., Bruce, R., & Prem-Senthil, M. (2022). A review of ocular complications associated with medications used for anxiety, depression, and stress. Clinical Optometry, 14, 13–25. https://doi.org/10.2147/OPTO.S355091
   PubMed Web of Science ®Google Scholar
• Davies, S., Hungerford, J., Arden, G., Marcus, R., Miller, M., & Huehns, E. (1983). Ocular toxicity of high-dose intravenous desferrioxamine. Lancet (London, England), 2(8343), 181–184. https://doi.org/10.1016/s0140-6736(83)90170-8
   PubMed Web of Science ®Google Scholar
• de Freitas, R. F., & Schapira, M. (2017). A systematic analysis of atomic protein–ligand interactions in the PDB. Medchemcomm, 8(10), 1970–1981. https://doi.org/10.1039/c7md00381a
   PubMed Web of Science ®Google Scholar
• FDA. (2018). Think it through: managing the benefits and risks of medicines. FDA.
   Google Scholar
• Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H., & Sparreboom, A. (2009). Contribution of organic cation transporter 2 (OCT2) to cisplatin‐induced nephrotoxicity. Clinical Pharmacology and Therapeutics, 86(4), 396–402. https://doi.org/10.1038/clpt.2009.139
   PubMed Web of Science ®Google Scholar
• Fiser, A. (2010). Template-based protein structure modeling. Methods in Molecular Biology, 673, 73–94. https://doi.org/10.1007/978-1-60761-842-3_6
   PubMedGoogle Scholar
• Fraunfelder, F. F. T., & Fraunfelder, F. R. W. (2021). Drug-induced ocular side effects (8th ed.), edited by F. F. T. Fraunfelder and F. R. W. Fraunfelder, iii. Elsevier.
   Google Scholar
• Gapsys, V., & de Groot, B. L. (2020). On the importance of statistics in molecular simulations for thermodynamics, kinetics and simulation box size. eLife, 9, e57589. https://doi.org/10.7554/eLife.57589
   PubMed Web of Science ®Google Scholar
• Garrett, Q., Xu, S., Simmons, P. A., Vehige, J., Flanagan, J. L., & Willcox, M. D. (2008). Expression and localization of carnitine/organic cation transporter OCTN1 and OCTN2 in ocular epithelium. Investigative Ophthalmology & Visual Science, 49(11), 4844–4849. https://doi.org/10.1167/iovs.07-1528
   PubMed Web of Science ®Google Scholar
• Gherghel, D. (2020). Ocular side effects of systemic drugs 1: Cholesterol lowering, anti-hypertensive and cardiac drugs. Optician, 2020(3), 8236–1. https://doi.org/10.12968/opti.2020.3.8236
   Google Scholar
• Ghosh, R., Chakraborty, A., Biswas, A., & Chowdhuri, S. (2021). Evaluation of green tea polyphenols as novel corona virus (SARS CoV-2) main protease (Mpro) inhibitors–an in silico docking and molecular dynamics simulation study. Journal of Biomolecular Structure & Dynamics, 39(12), 4362–4374. https://doi.org/10.1080/07391102.2020.1779818
   PubMed Web of Science ®Google Scholar
• Guo, D., Yang, H., Li, Q., Bae, H. J., Obianom, O., Zeng, S., Su, T., Polli, J. E., & Shu, Y. (2018). Selective inhibition on organic cation transporters by carvedilol protects mice from cisplatin-induced nephrotoxicity. Pharmaceutical Research, 35(11), 1–10. https://doi.org/10.1007/s11095-018-2486-2
   Web of Science ®Google Scholar
• Hafey, M. J., Aleksunes, L. M., Bridges, C. C., Brouwer, K. R., Chien, H.-C., Leslie, E. M., Hu, S., Li, Y., Shen, J., Sparreboom, A., Sprowl, J., Tweedie, D., & Lai, Y. (2022). Transporters and toxicity: Insights from the International Transporter Consortium Workshop 4. Clinical Pharmacology and Therapeutics, 112(3), 527–539. https://doi.org/10.1002/cpt.2638
   PubMed Web of Science ®Google Scholar
• Hendrickx, R., Johansson, J. G., Lohmann, C., Jenvert, R.-M., Blomgren, A., Börjesson, L., & Gustavsson, L. (2013). Identification of novel substrates and structure–activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. Journal of Medicinal Chemistry, 56(18), 7232–7242. https://doi.org/10.1021/jm400966v
   PubMed Web of Science ®Google Scholar
• Hermanto, F. E., Warsito, W., Rifa’i, M., & Widodo, N. (2022). Understanding hypocholesterolemic activity of soy isoflavones: Completing the puzzle through computational simulations. Journal of Biomolecular Structure and Dynamics, 1–7. https://doi.org/10.1080/07391102.2022.2148752
   Web of Science ®Google Scholar
• Hollingsworth, S. A., & Dror, R. O. (2018). Molecular dynamics simulation for all. Neuron, 99(6), 1129–1143. https://doi.org/10.1016/j.neuron.2018.08.011
   PubMed Web of Science ®Google Scholar
• Hub, J. S., de Groot, B. L., Grubmüller, H., & Groenhof, G. (2014). Quantifying artifacts in Ewald simulations of inhomogeneous systems with a net charge. Journal of Chemical Theory and Computation, 10(1), 381–390. https://doi.org/10.1021/ct400626b
   PubMed Web of Science ®Google Scholar
• Jain, S., & Ecker, G. F. (2019). In silico approaches to predict drug-transporter interaction profiles: Data mining, model generation, and link to cholestasis. Methods in Molecular Biology (Clifton, N.J.), 1981, 383–396. https://doi.org/10.1007/978-1-4939-9420-5_26
   PubMedGoogle Scholar
• Jensen, O., Brockmöller, J., & Dücker, C. (2021). Identification of novel high-affinity substrates of OCT1 using machine learning-guided virtual screening and experimental validation. Journal of Medicinal Chemistry, 64(5), 2762–2776. https://doi.org/10.1021/acs.jmedchem.0c02047
   PubMed Web of Science ®Google Scholar
• Khuri, N., & Deshmukh, S. (2018). Machine Learning for Classification of Inhibitors of Hepatic Drug Transporters [Paper presentation]. 2018 17th IEEE International Conference on Machine Learning and Applications (ICMLA). https://doi.org/10.1109/ICMLA.2018.00034
   Google Scholar
• Koepsell, H. (2004). Polyspecific organic cation transporters: Their functions and interactions with drugs. Trends in Pharmacological Sciences, 25(7), 375–381. https://doi.org/10.1016/j.tips.2004.05.005
   PubMed Web of Science ®Google Scholar
• Koepsell, H. (2011). Substrate recognition and translocation by polyspecific organic cation transporters.
   Google Scholar
• Koshy, C., Parthiban, M., & Sowdhamini, R. (2010). 100 ns molecular dynamics simulations to study intramolecular conformational changes in Bax. Journal of Biomolecular Structure & Dynamics, 28(1), 71–83. https://doi.org/10.1080/07391102.2010.10507344
   PubMed Web of Science ®Google Scholar
• Kubo, Y., Tsuchiyama, A., Shimizu, Y., Akanuma, S-i., & Hosoya, K-i (2014). Involvement of carrier-mediated transport in the retinal uptake of clonidine at the inner blood–retinal barrier. Molecular Pharmaceutics, 11(10), 3747–3753. https://doi.org/10.1021/mp500516j
   PubMed Web of Science ®Google Scholar
• Li, J., Tripathi, R. C., & Tripathi, B. J. (2008). Drug-induced ocular disorders. Drug Safety, 31(2), 127–141. https://doi.org/10.2165/00002018-200831020-00003
   PubMed Web of Science ®Google Scholar
• Liang, C., Peyman, G. A., & Federman, J. (1996). Ocular toxicity of intravitreous transforming growth factor-beta 1. Eye, 10(6), 709–713. https://doi.org/10.1038/eye.1996.165
   PubMedGoogle Scholar
• Liu, C. Y., Francis, J. H., Pulido, J., & Abramson, D. (2018). Ocular side effects of systemically administered chemotherapy. UpToDate.
   Google Scholar
• Liu, H. C., Goldenberg, A., Chen, Y., Lun, C., Wu, W., Bush, K. T., Balac, N., Rodriguez, P., Abagyan, R., & Nigam, S. K. (2016). Molecular properties of drugs interacting with SLC22 transporters OAT1, OAT3, OCT1, and OCT2: A machine-learning approach. The Journal of Pharmacology and Experimental Therapeutics, 359(1), 215–229. https://doi.org/10.1124/jpet.116.232660
   PubMed Web of Science ®Google Scholar
• Liu, K., & Kokubo, H. (2017). Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations: A cross-docking study. Journal of Chemical Information and Modeling, 57(10), 2514–2522. https://doi.org/10.1021/acs.jcim.7b00412
   PubMed Web of Science ®Google Scholar
• Lomize, M. A., Lomize, A. L., Pogozheva, I. D., & Mosberg, H. I. (2006). OPM: Orientations of proteins in membranes database. Bioinformatics (Oxford, England), 22(5), 623–625. https://doi.org/10.1093/bioinformatics/btk023
   PubMed Web of Science ®Google Scholar
• Meyer, M. J., & Tzvetkov, M. V. (2021). OCT1 polyspecificity—Friend or foe? Frontiers in Pharmacology, 12, 698153. https://doi.org/10.3389/fphar.2021.698153
   PubMed Web of Science ®Google Scholar
• Misaka, S., Knop, J., Singer, K., Hoier, E., Keiser, M., Müller, F., Glaeser, H., König, J., & Fromm, M. F. (2016). The nonmetabolized β-blocker nadolol is a substrate of OCT1, OCT2, MATE1, MATE2-K, and P-glycoprotein, but not of OATP1B1 and OATP1B3. Molecular Pharmaceutics, 13(2), 512–519. https://doi.org/10.1021/acs.molpharmaceut.5b00733
   PubMed Web of Science ®Google Scholar
• Moorthy, R. S., & Valluri, S. (1999). Ocular toxicity associated with systemic drug therapy. Current Opinion in Ophthalmology, 10(6), 438–446. https://doi.org/10.1097/00055735-199912000-00012
   PubMedGoogle Scholar
• Mukhtar, S., & Jhanji, V. (2022). Effects of systemic targeted immunosuppressive therapy on ocular surface. Current Opinion in Ophthalmology, 33(4), 311–317. https://doi.org/10.1097/ICU.0000000000000860
   PubMed Web of Science ®Google Scholar
• Nagy, T., Tóth, Á., Telbisz, Á., Sarkadi, B., Tordai, H., Tordai, A., & Hegedűs, T. (2021). The transport pathway in the ABCG2 protein and its regulation revealed by molecular dynamics simulations. Cellular and Molecular Life Sciences : CMLS, 78(5), 2329–2339. https://doi.org/10.1007/s00018-020-03651-3
   PubMed Web of Science ®Google Scholar
• Neuhoff, S., Ungell, A.-L., Zamora, I., & Artursson, P. (2003). pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: Implications for drug–drug interactions. Pharmaceutical Research, 20(8), 1141–1148. https://doi.org/10.1023/a:1025032511040
   PubMed Web of Science ®Google Scholar
• Nirmal, J., Sirohiwal, A., Singh, S. B., Biswas, N. R., Thavaraj, V., Azad, R. V., & Velpandian, T. (2013). Role of organic cation transporters in the ocular disposition of its intravenously injected substrate in rabbits: Implications for ocular drug therapy. Experimental Eye Research, 116, 27–35. https://doi.org/10.1016/j.exer.2013.07.004
   PubMed Web of Science ®Google Scholar
• Nirmal, J. V. T., Biswas, N. R., Azad, R. V., Vasantha, T., Bhatnagar, A., & Ghose, S. (2010). Evaluation of the relevance of OCT blockade on the transcorneal kinetics of topically applied substrates using rabbits. FIP 2010 World Congress in association with AAPS , New Orleans, USA, Nov.
   Google Scholar
• OECD. (2020). Overview of concepts and available guidance related to integrated approaches to testing and assessment (IATA). In Series on Testing and Assesment No. 329, edited by Environment, Health and Safety, Environment Directorate, OECD.
   Google Scholar
• OECD. (2021). “The OECD QSAR Toolbox.” https://www.oecd.org/chemicalsafety/risk-assessment/oecd-qsar-toolbox.html. OECD. Retrieved 07/10/2022.
   Google Scholar
• Police, A., Shankar, V. K., & Murthy, S. N. (2020). Role of taurine transporter in the retinal uptake of vigabatrin. AAPS PharmSciTech, 21(5), 1–9. https://doi.org/10.1208/s12249-020-01736-7
   Web of Science ®Google Scholar
• Popp, C., Gorboulev, V., Müller, T. D., Gorbunov, D., Shatskaya, N., & Koepsell, H. (2005). Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Molecular Pharmacology, 67(5), 1600–1611. https://doi.org/10.1124/mol.104.008839
   PubMed Web of Science ®Google Scholar
• Prakash, B., Kumar, H. M., Palaniswami, S., & Lakshman, B. H. (2019). Ocular side effects of systemic drugs used in dermatology. Indian Journal of Dermatology, 64(6), 423–430. https://doi.org/10.4103/ijd.IJD_353_18
   PubMed Web of Science ®Google Scholar
• Pu, L., Naderi, M., Liu, T., Wu, H.-C., Mukhopadhyay, S., & Brylinski, M. (2019). e toxpred: A machine learning-based approach to estimate the toxicity of drug candidates. BMC Pharmacology & Toxicology, 20(1), 2. https://doi.org/10.1186/s40360-018-0282-6
   PubMedGoogle Scholar
• Ramachandran, G. t., & Sasisekharan, V. (1968). Conformation of polypeptides and proteins. Advances in Protein Chemistry, 23, 283–438.
   PubMedGoogle Scholar
• Redeker, K.-E M., Jensen, O., Gebauer, L., Meyer-Tönnies, M. J., & Brockmöller, J. (2022). Atypical substrates of the organic cation transporter 1. Biomolecules, 12(11), 1664. https://doi.org/10.3390/biom12111664
   PubMed Web of Science ®Google Scholar
• Richa, S., & Yazbek, J.-C. (2010). Ocular adverse effects of common psychotropic agents. CNS Drugs, 24(6), 501–526. https://doi.org/10.2165/11533180-000000000-00000
   PubMed Web of Science ®Google Scholar
• Santaella, R. M., & Fraunfelder, F. W. (2007). Ocular adverse effects associated with systemic medications. Drugs, 67(1), 75–93. https://doi.org/10.2165/00003495-200767010-00006
   PubMed Web of Science ®Google Scholar
• Schlessinger, A., Welch, M. A., van Vlijmen, H., Korzekwa, K., Swaan, P. W., & Matsson, P. (2018). Molecular modeling of drug-transporter interactions-An international transporter consortium perspective. Clinical Pharmacology and Therapeutics, 104(5), 818–835. https://doi.org/10.1002/cpt.1174
   PubMed Web of Science ®Google Scholar
• Shin, E., Lim, D. H., Han, J., Nam, D.-H., Park, K., Ahn, M.-J., Kang, W. K., Lee, J., Ahn, J. S., Lee, S.-H., Sun, J.-M., Jung, H. A., & Chung, T.-Y. (2020). Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. BMC Ophthalmology, 20(1), 19. https://doi.org/10.1186/s12886-019-1285-9
   PubMed Web of Science ®Google Scholar
• Shoichet, B. K., Leach, A. R., & Kuntz, I. D. (1999). Ligand solvation in molecular docking. Proteins: Structure, Function, and Genetics, 34(1), 4–16. https://doi.org/10.1002/(SICI)1097-0134(19990101)34:1<4::AID-PROT2>3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Tehrani, R., Ostrowski, R. A., Hariman, R., & Jay, W. M. (2008). Ocular toxicity of hydroxychloroquine. Seminars in Ophthalmology, 23(3), 201–209. https://doi.org/10.1080/08820530802049962
   PubMedGoogle Scholar
• Valsson, O., Tiwary, P., & Parrinello, M. (2016). Enhancing important fluctuations: Rare events and metadynamics from a conceptual viewpoint. Annual Review of Physical Chemistry, 67(1), 159–184. https://doi.org/10.1146/annurev-physchem-040215-112229
   PubMedGoogle Scholar
• Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., Li, B., Madabhushi, A., Shah, P., Spitzer, M., & Zhao, S. (2019). Applications of machine learning in drug discovery and development. Nature Reviews. Drug Discovery, 18(6), 463–477. https://doi.org/10.1038/s41573-019-0024-5
   PubMed Web of Science ®Google Scholar
• Velpandian, T., Nirmal, J., Sirohiwal, A., Singh, S. B., Vasantha, T., Azad, R. V., & Ghose, S. (2012). Evaluation of the modulation of Organic Cation Transporter (OCT) in the Tear Disposition of its Substrates in Rabbits. Investigative Ophthalmology & Visual Science, 53(14), 5333–5333.
   Google Scholar
• Vishnevskia-Dai, V., Rozner, L., Berger, R., Jaron, Z., Elyashiv, S., Markel, G., & Zloto, O. (2021). Ocular side effects of novel anti-cancer biological therapies. Scientific Reports, 11(1), 787. https://doi.org/10.1038/s41598-020-80898-7
   PubMed Web of Science ®Google Scholar
• Weng, Y. L., Naik, S. R., Dingelstad, N., Lugo, M. R., Kalyaanamoorthy, S., & Ganesan, A. (2021). Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity. Scientific Reports, 11(1), 7429. https://doi.org/10.1038/s41598-021-86471-0
   PubMed Web of Science ®Google Scholar
• Yuan, X., Feng, Y., Li, D., & Li, M. (2019). Unilateral visual impairment in a patient undergoing chemotherapy: A case report and clinical findings. BMC Ophthalmology, 19(1), 236. https://doi.org/10.1186/s12886-019-1246-3
   PubMed Web of Science ®Google Scholar
• Zhang, T., Xiang, C. D., Gale, D., Carreiro, S., Wu, E. Y., & Zhang, E. Y. (2008). Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: Implications for ocular drug disposition. Drug Metabolism and Disposition: The Biological Fate of Chemicals, 36(7), 1300–1307. https://doi.org/10.1124/dmd.108.021121
   PubMed Web of Science ®Google Scholar